Influence of the folate pathway and transporter polymorphisms on methotrexate treatment outcome in osteosarcoma.

摘要

We have shown that SLCO1B1 polymorphisms influence methotrexate disposition and survival in methotrexate-treated osteosarcoma patients and therefore might serve as pharmacogenetic markers of treatment outcome.